About PMV Pharmaceuticals, Inc.
https://www.pmvpharma.comPMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.
CEO
David H. Mack
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:5.98M
Value:$6.81M
BML CAPITAL MANAGEMENT, LLC
Shares:5.29M
Value:$6.03M
TANG CAPITAL MANAGEMENT LLC
Shares:4.79M
Value:$5.46M
Summary
Showing Top 3 of 78
About PMV Pharmaceuticals, Inc.
https://www.pmvpharma.comPMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $22.49M ▼ | $-21.06M ▲ | 0% | $-0.4 ▲ | $-21.03M ▲ |
| Q2-2025 | $0 | $22.85M ▲ | $-21.21M ▼ | 0% | $-0.41 ▼ | $-21.17M ▲ |
| Q1-2025 | $0 | $21.56M ▼ | $-17.44M ▲ | 0% | $-0.34 ▼ | $-21.53M ▲ |
| Q4-2024 | $0 | $25.17M ▲ | $-23M ▼ | 0% | $0.37 ▲ | $-25.13M ▼ |
| Q3-2024 | $0 | $21.89M | $-19.23M | 0% | $-0.37 | $-21.52M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $129.25M ▼ | $133.84M ▼ | $12.85M ▲ | $121M ▼ |
| Q2-2025 | $142.27M ▼ | $152.85M ▼ | $12.25M ▲ | $140.6M ▼ |
| Q1-2025 | $160.39M ▼ | $170.61M ▼ | $10.5M ▼ | $160.11M ▼ |
| Q4-2024 | $169.45M ▼ | $191.29M ▼ | $15.21M ▼ | $176.08M ▼ |
| Q3-2024 | $182.84M | $223.5M | $25.59M | $197.91M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-21.06M ▲ | $-19.82M ▼ | $12.03M ▲ | $0 ▼ | $-7.79M ▼ | $-19.82M ▼ |
| Q2-2025 | $-21.21M ▼ | $-18.3M ▼ | $10.99M ▼ | $103K ▲ | $-7.21M ▼ | $-18.31M ▼ |
| Q1-2025 | $-17.44M ▲ | $-18.27M ▼ | $28.71M ▲ | $10K ▼ | $10.46M ▲ | $-18.27M ▼ |
| Q4-2024 | $-23M ▼ | $-16.66M ▲ | $7.74M ▼ | $172K ▲ | $-8.76M ▼ | $-16.72M ▲ |
| Q3-2024 | $-19.23M | $-16.84M | $17.12M | $0 | $284K | $-16.84M |
CEO
David H. Mack
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:5.98M
Value:$6.81M
BML CAPITAL MANAGEMENT, LLC
Shares:5.29M
Value:$6.03M
TANG CAPITAL MANAGEMENT LLC
Shares:4.79M
Value:$5.46M
Summary
Showing Top 3 of 78